Skip to content

persevERA — Giredestrant + palbociclib, 1L ER+/HER2− locally advanced or metastatic breast cancer

Abstract: LBA1006 · Session: Oral Abstract Session — Breast Cancer—Metastatic, Tue Jun 2, 2026, 11:45–11:57 AM CT · Presenter: Nicholas C. Turner, MD, PhD (The Royal Marsden / Institute of Cancer Research, London) · Embargo: Jun 2, 2026

At a glance

  • Sponsor: Roche / Genentech
  • PI / presenter: Nicholas C. Turner, MD, PhD
  • NCT ID: NCT04546009
  • Phase: III
  • Design: Randomized, double-blind, placebo-controlled, multicenter — giredestrant + palbociclib vs letrozole + palbociclib
  • N: 992 (enrolled globally)
  • Primary endpoint(s): Investigator-assessed progression-free survival (PFS), ITT
  • Comparator: Letrozole + palbociclib
  • Indication: ER-positive, HER2-negative locally advanced or metastatic breast cancer
  • Line: First-line (no prior systemic therapy for advanced disease)

Headline result

The phase III persevERA trial missed its primary endpoint: giredestrant + palbociclib produced a numerical but not statistically significant improvement in investigator-assessed PFS versus letrozole + palbociclib in the ITT population of 1L ER+/HER2− advanced breast cancer. Roche/Genentech first disclosed the negative topline on March 9, 2026 (per Roche/Genentech topline, Mar 9, 2026); the primary analysis was presented at ASCO 2026 (LBA1006). Safety was manageable and consistent with the known profiles of each agent. Specific median PFS values by arm, the hazard ratio with 95% CI, and the p-value were not disclosed in the publicly available pre-meeting and trade-press sources at time of writing. Secondary endpoints (OS, ORR, DoR) remain immature/ongoing.

Mechanism / class

Giredestrant (GDC-9545) is a next-generation oral selective estrogen receptor degrader (SERD) and full ER antagonist; it is investigational (not yet FDA-approved) but has an FDA-accepted NDA in advanced breast cancer on the strength of the positive evERA study (giredestrant + everolimus), and showed positive iDFS in the adjuvant lidERA trial. Palbociclib (Ibrance) is an approved CDK4/6 inhibitor; letrozole is a standard nonsteroidal aromatase inhibitor. The trial tested whether substituting an oral SERD for an aromatase-inhibitor backbone could improve frontline endocrine efficacy.

Discussant takeaway

Pre-meeting expert framing (CancerNetwork ASCO 2026 breast preview; Targeted Oncology) held that the result adds complexity to giredestrant's role — "oral SERDs aren't ready to displace this combination" in the frontline setting, and combinations require further optimization and clearer sequencing with CDK4/6 inhibitors. The clinical read hinges on the magnitude and confidence intervals of the PFS delta and on whether a biomarker-defined subgroup (e.g., ESR1 wild-type, low prior endocrine exposure) shows a pursuable signal — set against the contrasting positive lidERA (adjuvant) and evERA (later-line) results. Named on-site discussant framing not captured in available sources; omitted.

Practice-changing?

No. A missed primary PFS endpoint in the 1L setting means giredestrant + palbociclib does not displace standard aromatase-inhibitor + CDK4/6i frontline therapy in endocrine-sensitive ER+/HER2− advanced breast cancer. The result narrows the role of oral SERDs to settings where they have shown benefit (adjuvant lidERA; endocrine-resistant/later-line evERA) and raises the question of which patients, if any, derive 1L benefit. The program continues in early breast cancer.

Sources